Discrepancies exist between the care of unrelated donors (UDs) and related donors (RDs), particularly regarding medical suitability criteria, consenting procedures and donor follow-up. Changes to the most recent JACIE standards have addressed these issues. We studied 208 RDs who underwent PBSC or BM donation in a single centre during 2004-2013 to determine the impact of regulatory changes on donor care, and assessed the safety and efficacy of stem cell donation in donors not meeting UD medical suitability criteria. We observed significant improvements in donor consenting procedures (P = 0.003) and donor follow-up (P = 0.007) after stipulations in these areas were introduced. We saw a higher incidence of serious adverse events (SAEs) in RDs not meeting UD suitability criteria (P = 0.018), and a higher incidence of SAEs in donors ⩾ 60 years (P = 0.020). Haematopoietic progenitor cell donation is less safe in RDs who do not meet UD criteria for medical suitability. Although changes to JACIE standards have improved practice, development of specific medical suitability for RDs and guidelines around 'grey areas' where risks to a donor are unclear or theoretical, will be important in improving RD safety and standardising practice.
INTRODUCTION
Surveys performed in the United States 1 and Europe 2,3 have outlined the variability in related donor (RD) care and drawn attention to the lack of regulatory guidance in this field. 4 Concerns raised include potential conflict of interest when the same team is simultaneously involved in the care of a RD and their recipient, the absence of standardised medical eligibility criteria and the lack of centralised RD follow-up.
Although there is a paucity of prospective information concerning adverse incidents in RDs, there are indications that donation risks are greater in the RD setting. Retrospective studies by the European Society for Blood and Marrow Transplantation (EBMT) 5 and World Health Organization 6 have described a number of fatal adverse events (AEs) in RDs, whereas other studies have shown an increased incidence of serious adverse events (SAEs) in RDs not meeting unrelated donor (UD) suitability criteria. 7, 8 Following these publications, the Joint Accreditation Committee ISCT and EBMT (JACIE)/Foundation for the Accreditation of Cellular Therapy (FACT) introduced specific standards to address RD care. In April 2011, the fourth FACT-JACIE Standards 9 introduced a requirement for 'a policy for follow-up of allogeneic donors that includes routine management and the management of donationassociated AEs'. The fifth Standards published in March 2012 then stipulated that allogeneic donors should be assessed by a 'licensed health-care professional who is not the primary transplant physician overseeing care of the recipient'. 9 Similar and further recommendations have been made by other bodies: a World Marrow Donor Association (WMDA) working group published recommendations for family donor care 10 focusing on consenting procedures (including that donors should be offered choice of donation route), health assessment pre-tissue typing and donor follow-up. In 2013, a consensus paper on standardised assessment of donor outcome 11 was published under the umbrella of the Worldwide Network for Blood and Marrow Transplantation (WBMT). In general, the suitability criteria with which RDs are assessed in transplant centres are less stringent than those of UDs, 1,2 however, an increased rate of RD deferrals (many for age alone) would be seen if current UD criteria were employed in the RD setting. Furthermore, WMDA standards for evaluation of UDs 12 were developed for donors under the age of 55-60 years, and the optimal approach to older donors is unclear, that is, whether additional screening procedures are warranted. 13, 14 A further potential concern when considering the use of older haematopoietic progenitor cell donors is the quality of stem cells harvested. Older age (455) correlated with lower CD34 + cell yields in some studies [14] [15] [16] but despite this, adequate engraftment occurred, and medically fit older donors usually harvest adequate CD34 + cells to allow transplantation to proceed. [15] [16] [17] As yet, no studies have investigated the impact that changes to regulatory guidance have had on clinical practice.
In this study, we investigated how changes in JACIE standards have influenced practice in a single transplant centre, and retrospectively assessed how deferral patterns would have differed if related donors had been assessed using national UD criteria. We assessed safety and efficacy of donation in related donors not meeting UD criteria and questioned whether medical issues in donors who failed at the point of donor medical could have been identified earlier if more extensive pre-HLA-typing screening was employed.
MATERIALS AND METHODS
Details of all allogeneic donors donating from January 2004 to December 2013 were obtained from the Royal Marsden hospital-specific electronic database. The recipients were all patients treated in the hospital's transplant unit. Typing results of 879 relatives of 485 patients from the Anthony Nolan database were reviewed to identify further patients with a matched RD who did not proceed to donation.
Adult donor suitability status was retrospectively assessed using the Anthony Nolan medical guidelines, (available at http://med-guidelines.org. uk, accessed on 12 November 2013).
We reviewed all events occurring from the start of mobilization to 30 days post donation. Any AEs requiring admission to hospital, modification of the mobilization regimen or apheresis procedure, or unscheduled medical treatment were classed as severe. Relationships between severe AEs and categorical donor characteristics were examined using χ 2 or Fisher's exact test where appropriate. As non-severe AEs such as bone pain and citrate toxicity are well described in donors, examining factors associated with these was not the purpose of this study.
The Institutional Review Board at Anthony Nolan approved the study. All donors signed informed consent before donation.
RESULTS
The data pertaining to 221 consecutive allogeneic donations were collected from the donor electronic medical records. From this total, four were excluded because they used frozen haematopoietic progenitor cells collected before the study period, and a further donation was excluded because cord blood from a sibling was used.
Donor characteristics A total of 216 donations from 208 RDs were analysed (8 siblings donated PBSC twice). In all, 205 donors were fully matched siblings, 1 was a fully matched mother, 1 was a fully matched cousin and 1 was a haplo-identical son.
The median RD age at donation was 43.5 years (range 22 months-74 years), 92 RDs were female and 118 were male. In all, 37 donors underwent BM harvest, whereas 179 PBSC donations occurred. All 31 RDs under 16 years donated BM.
The median recipient age was 48.1 years (range 2-74 years), with a total of 30 paediatric (o 16 years) patients.
Effect of changes to JACIE Standards on donor management Before introduction of the fifth Edition JACIE Standards, the same doctor consented both the RD and their recipient in 34/173 (20%) donations, compared with 0/43 donations after these standards were introduced (P = 0.003). In 11 of these 43 cases (26%), the doctor consenting the RD had, however, been actively involved in the care of the recipient within the last month.
We also found that consent discussions had become more detailed over time, particularly with respect to donor choice of PBSC or BM donation. After guidelines recommending that donors were offered a choice of donation route were published in 2010, 80% adult donors were offered this choice, compared with 33% before 2010 (P o 0.001).
Before JACIE Standards introduced a requirement for donor follow-up (April 2011), 60/161 (37%) donors were offered followup beyond 1 week post donation, in comparison to 32/55 (58%) after this point (P = 0.007).
Retrospective evaluation of adult RDs using the Anthony Nolan medical suitability criteria On retrospective assessment of adult RD records using the Anthony Nolan medical suitability criteria, in 53/185 (28.6%) cases the RD would have been deferred. The most common reasons for deferral ( We evaluated the relationship between AEs and donor characteristics. As outlined in Table 2 , five adult RDs (2.7%) experienced SAEs. RDs aged 460 years were more likely to develop SAEs (10.3% vs 1.3%, P = 0.020) and adults who would not be accepted as UDs because of increased risk to donor health, experienced significantly more SAEs (8% vs 0.7%, P = 0.018). No impact of donor sex was seen.
SAEs in paediatric donors
One paediatric donor aged 22 months, received an allogeneic red cell transfusion following BM harvest due to a post procedure Hb level of 62 g/L. This was the sole AE among paediatric donors.
Effect of age on cell dose A median of 4.83X10 6 CD34 + cells/kg recipient weight were harvested from PBSC donors, with no significant difference in cell dose or number of apheresis procedures between older and younger donors or between sexes.
BM donors harvested a median 2.66x10 6 /kg CD34 + cells (range 0.11-11.45), with an increased probability of not reaching the target CD34 + cell dose of 4x10 6 /kg for paediatric RDs donating to an older sibling (P = 0.031). Sickle trait undergoing PBSC donation; Gout 3 weeks pre-PBSC donation; endometrial cancer; gene repair defect msh2; previous intravenous drug user; central nervous system symptoms following head injury; multinodular goitre awaiting surgery; severe chronic back pain and paraesthesia; SVT pre-ablation; ischaemic heart disease. Impact of JACIE standards on related donor care C Anthias et al Donor follow-up During the study period, a total of 95 donor follow-up years was achieved, with annual medical questionnaires to collect the recommended donor follow-up minimum data set. 11 Questionnaires were sent to 65% donors; for the remainder of donors only a temporary address had been recorded at the time of donation (because the donor lived overseas) and follow-up was therefore impossible. 56% donors contacted responded to follow-up questionnaires, with RDs whose recipient had died less likely to return follow-up questionnaires (31% vs 66%, P = 0.020).
Six donors described new medical issues at follow-up (detailed in Table 3 ), none of which were felt to be donation related.
Matched donors who did not proceed to donation Twenty-three patients over the study period had at least one matched sibling identified, but did not proceed to transplant. In 11 cases, this was due to the patient experiencing progressive disease or becoming medically unfit for allograft, whereas in 9 cases alternative treatment was recommended. In one case, an allograft was recommended but did not take place because of cost involved in the RD travelling from overseas, and reluctance on the part of the potential donor.
A further seven siblings were scheduled to donate but failed medical assessment, all in 2011-2013. Six failed for medical issues (described in Table 4 ), and one donor was excluded due to failure to abstain from high-risk practices. Interestingly, five out of seven of these sibling failed medical evaluation because of abnormal haematological indices. In three of these cases, two with eosinophilia and one with polycythaemia, it was felt that the donor could potentially have been used if further investigations were undertaken. However, these donors all lived overseas, and for logistical reasons around the delays performing further investigations or donor employment issues, in each of these cases the decision was made to use a previously identified wellmatched UD instead.
DISCUSSION
Following the introduction of JACIE standards addressing donor care, new Standard Operating Procedures were written, leading to significant improvements in donor consenting procedures and donor follow-up.
Overall, the incidence of SAEs (2%) was in line with other studies, 8 and we were able to identify predictive factors. We saw a higher incidence of SAEs in RDs not meeting UD suitability criteria and a higher incidence of SAEs in donors ⩾ 60 years.
Our data add to previously published studies showing that donation is less safe in RDs who do not meet UD medical suitability criteria. 7, 8 However, the deferral rate in our study population would have been very high (28.6%) if national UD criteria were strictly adhered to, incurring a logistical and financial burden on transplant centres to acquire alternative donors (as well as a delayed transplant). If age were not included as a deferral criterion, this high deferral rate would have fallen to 18.4% adults, illustrating the need for a better understanding of risks in older donors.
Stem cell donation is generally a safe procedure and there is no evidence that every donor 460 years should be excluded, but consideration should be given to more stringent screening procedures to exclude age-associated morbidities in this group, as well as to prevent transmission of donor illnesses. 13 In both our study and other reports, cardiovascular complications constitute the majority of SAEs. We recommend that all donors 460 years undergo careful evaluation focused on identification of occult cardiovascular disease and cardiovascular risk factors. Where 41 risk factor is present there should be a low threshold for specialist review before acceptance for donation. The increase in donationrelated risks in older donors should form part of the informed consent discussion.
Medical conditions, which have been strongly associated with donation-related morbidity and mortality (for example, uncontrolled hypertension and cardiovascular disease) 5, 7 should confer an automatic deferral. The risks associated with many other donor factors/conditions are less well understood. A large prospective study currently underway in the United States of America, RDSafe (related donor safety study), 18 is directly addressing this issue, and will provide an evidence base for development of specific RD medical suitability criteria.
The approach to RDs in whom risks of donation are potentially increased but are poorly defined is difficult. The assessing physician must balance the psychological and physical risks to a donor of donating versus not donating. Independent assessment and donor advocacy is crucial, but additional procedures for psychological assessment and involvement of an independent committee may be necessary in some situations.
Implementation of improved JACIE Standards in our hospital significantly enhanced consenting procedures but physicians assessing the donors were, in many cases, nevertheless, involved in the recipients care. Transplant physicians are not uniquely able to evaluate stem cell donors; we recommend that to prevent a Impact of JACIE standards on related donor care C Anthias et al conflict of interest, RDs should be evaluated by a health-care professional who is not part of the team caring for the recipient. This could be non-transplant haematologist or a physician from a separate medical speciality; the crux is that this donor assessor should undergo specific training in donor health, and should evaluate the donor independently, without consideration of the clinical situation of the patient. Almost 50% RDs received no follow-up beyond 1 week post donation. Understandably, donors whose recipient had died were less likely to respond to contact from their relative's transplant centre. These donors may find it more acceptable to be followed up by an organization separate to the centre where their relative was treated and alternative systems for RD follow-up will be an area for further exploration. Recent international efforts have promoted long-term follow-up for both RD and UD. 11, 19 Since 2012, donor outcome forms have been available via the EBMT database under the guidance of the EBMT Donor Outcome committee in collaboration with the Swiss Transfusion SRC, enabling collective recording of RD data.
Following the findings of this study, UK guidelines for RD care are being written by an expert group. A CIBMTR study is also ongoing, examining the impact of FACT JACIE Standards in an international multi-centre setting. The initiatives will be key to providing a basis for standardised donor care. They will be more effective, however, if implementation is supported by further development of JACIE Standards around donor care.
